Lisata Therapeutics (Nasdaq: LSTA) has been granted Rare Pediatric Disease Designation by the FDA for LSTA1, the company’s lead product candidate, for the treatment of…
Next-generation psychedelics company, Cybin, Inc (NYSE American: CYBN) has closed an oversubscribed private placement of 348,837,210 common shares at a price of $0.43 per share,…
March 21, 2024
Bionomics Candidate Offers Hope for 13 Million Americans Living with Post-Traumatic Stress
Clinical-stage biotechnology company, Bionomics Limited (Nasdaq: BNOX), is offering hope to the more than 13 million Americans living with post-traumatic stress disorder (PTSD), a debilitating…
Enveric Biosciences (Nasdaq: ENVB) has signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds. The…
Psychedelic drug company, Clearmind Medicine Inc. (Nasdaq: CMND), has received approval from the Israeli Ministry of Health to commence its Phase 1/2a clinical trial for…
Clinical stage biopharmaceutical company, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), has received Institutional Review Board (IRB) approval of its Phase 2a clinical trial protocol to evaluate…
Marvel Biosciences Corp. (OTCQB: MBCOF) has reported promising interim results from its study on MB-204, a new treatment for autism. The study, being conducted by…
March 18, 2024
SciSparc Doses First Patient in Autism Treatment Trial
SciSparc Ltd. (Nasdaq: SPRC) has successfully dosed the first patient in its SCI-210 clinical trial for pediatric patients with Autism Spectrum Disorder (ASD). This is…
March 18, 2024
Fennec Pharmaceuticals to Commercialize Protective Treatment for Chemotherapy-Induced Hearing Loss
Shares in commercial stage pharmaceutical company, Fennec Pharmaceuticals Inc. (Nasdaq: FENC), rose 11% in morning trading on Monday after the company announced it will partner…
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has received Safety Review Committee (SRC) approvalrecommending that the company’s two-part Phase 2a trial of DA-1241, for the treatment of…
Artificial intelligence company, Lantern Pharma Inc. (Nasdaq: LTRN), is advancing a pipeline of AI-driven therapies to patients. On Friday, the company announced it has dosed…
Shares in Madrigal Pharmaceuticals (Nasdaq: MDGL) soared this week after the FDA granted accelerated approval of the company’s drug candidate Rezdiffra™ in the treatment of…